Takeda to Acquire LigoCyte Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda to Acquire LigoCyte Pharmaceuticals


ePT--the Electronic Newsletter of Pharmaceutical Technology

Takeda’s US subsidiary, Takeda America Holdings, has agreed to acquire the vaccine specialist company LigoCyte Pharmaceuticals for an upfront payment of $60 million in a move intended to bolster and expand the company’s vaccine business. Future payments may also be made depending on the progress of LigoCyte’s development projects.

LigoCyte is a US-based biopharmaceutical company that uses its proprietary virus-like particle (VLP) platform technology to develop new vaccines. The comapny’s lead product is a norovirus vaccine that can prevent multiple varieties of the illness. According to a press statement, the vaccine has been shown to provide protection against the norovirus in an initial human challenge trial. The company intends to seek approval for the vaccine in the US, Europe, and other regions.

LigoCyte has also begun preclinical development of other vaccines against respiratory syncytial virus, influenza, and rotavirus.

In a statement, Rajeev Venkayya, the executive vice-president of Takeda’s Vaccine Business Division, said, “Norovirus is the most common cause of outbreaks of gastroenteritis and foodborne illness in the US, and is responsible for 200,000 deaths each year, most of them in developing countries. With the only norovirus vaccine in clinical trials today, Takeda will be in a position to change this picture.”

Takeda intends to continue operating LigoCyte at its current location in Bozeman, Montana, for the foreseeable future and will retain the management team and its employees. Once the acquisition is complete, the management team will become a part of Takeda’s Vaccine Business Division, which was launched in January 2012.

The deal is expected to close by the end of November 2012, pending the satisfactory clearance of closing conditions.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here